Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H11IN2O5 |
Molecular Weight | 354.0985 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(I)C(=O)NC2=O
InChI
InChIKey=XQFRJNBWHJMXHO-RRKCRQDMSA-N
InChI=1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
Molecular Formula | C9H11IN2O5 |
Molecular Weight | 354.0985 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1316491/?page=1https://www.ncbi.nlm.nih.gov/pubmed/31337643 | https://clinicaltrials.gov/ct2/show/NCT02993146 | https://clinicaltrials.gov/ct2/show/NCT02381561 | https://www.drugbank.ca/drugs/DB06485Curator's Comment: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm;
http://www.ncbi.nlm.nih.gov/pubmed/9336833;
http://www.ncbi.nlm.nih.gov/pubmed/12705773;
http://www.ncbi.nlm.nih.gov/pubmed/14435162;
http://www.ncbi.nlm.nih.gov/pubmed/4309419
Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1316491/?page=1https://www.ncbi.nlm.nih.gov/pubmed/31337643 | https://clinicaltrials.gov/ct2/show/NCT02993146 | https://clinicaltrials.gov/ct2/show/NCT02381561 | https://www.drugbank.ca/drugs/DB06485
Curator's Comment: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm;
http://www.ncbi.nlm.nih.gov/pubmed/9336833;
http://www.ncbi.nlm.nih.gov/pubmed/12705773;
http://www.ncbi.nlm.nih.gov/pubmed/14435162;
http://www.ncbi.nlm.nih.gov/pubmed/4309419
Ropidoxuridine is a thymidine analogue and an oral prodrug of iododeoxyuridine that is easier to administer and less toxic with a more favorable therapeutic index in preclinical studies. Iododeoxyuridine demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor. Ropidoxuridine may help radiation therapy work better by making tumor cells more sensitive to the radiation therapy. In 2019, phase I clinical trials were ongoing to study the best dose of ropidoxuridine and its side effects in patients with metastatic malignant neoplasm in the brain and in patients with metastatic gastrointestinal cancer. First results showed that ropidoxuridine, combined with radiation therapy, was well-tolerated in patients with metastatic gastrointestinal cancer.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/2379179
Curator's Comment: In rat brain
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/13628760
Curator's Comment: Late 1950s
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2366042 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6243982 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DENDRID Approved UseFor the treatment of keratitis caused by the virus of herpes simplex. Launch Date-1.94227208E11 |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
139.03 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9661893/ |
4538 mg/m² 1 times / day multiple, intraperitoneal dose: 4538 mg/m² route of administration: Intraperitoneal experiment type: MULTIPLE co-administered: |
IDOXURIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. | 1976 Mar |
|
Interventions for herpes simplex virus epithelial keratitis. | 2001 |
|
Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. | 2001 Apr |
|
Antiviral drugs: current state of the art. | 2001 Aug |
|
Is there a future for cell kinetic measurements using IdUrd or BdUrd? | 2001 Feb 1 |
|
Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. | 2001 Feb 1 |
|
In vitro effects of antiviral agents on human keratocytes. | 2001 Jan |
|
A flow cytometry technique for measuring chromosome-mediated gene transfer. | 2001 Jun 1 |
|
Contact dermatitis from topical antiviral drugs. | 2001 May |
|
Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine. | 2001 Nov 1 |
|
Targeting DNA mismatch repair for radiosensitization. | 2001 Oct |
|
Ratio of complex double strand break damage induced by 125IUdR and 123IUdR correlates with experimental in vitro cell killing effectiveness. | 2002 |
|
Pharmacokinetics and metabolism of the novel synthetic C-nucleoside, 1-(2-deoxy-beta-D-ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine. | 2002 Apr |
|
Induction of chromosome aberrations in unirradiated chromatin after partial irradiation of a cell nucleus. | 2002 Apr |
|
Temporal changes in the distribution of thoracic duct lymphoblasts to synovium and other tissues of rats with adjuvant-induced arthritis. | 2002 Apr |
|
A new bacilliform fathead minnow rhabdovirus that produces syncytia in tissue culture. | 2002 May |
|
Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. | 2002 Oct |
|
Effect of 5-iodo-2'-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice. | 2002 Sep |
|
Study on the possibility of insulin as a carrier of IUdR for hepatocellular carcinoma-targeted therapy. | 2003 Aug |
|
Postherpetic neuralgia. | 2003 Dec |
|
A balanced deoxyribonucleoside mixture increased the rate of DNA incorporation of 5-[125I]Iodo-2'-deoxyuridine in glioblastoma cells. | 2003 Feb |
|
Preclinical Auger and gamma radiation dosimetry for fluorodeoxyuridine-enhanced tumour proliferation scintigraphy with [123I]iododeoxyuridine. | 2003 Feb |
|
Protease-activated receptor (PAR)-1 and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas. | 2003 Feb 1 |
|
Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization. | 2003 Feb 15 |
|
In vitro activity of potential anti-poxvirus agents. | 2003 Jan |
|
Postherpetic neuralgia. | 2003 Jun |
|
Design of Mycobacterium tuberculosis thymidine monophosphate kinase inhibitors. | 2003 May-Aug |
|
In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. | 2004 Apr |
|
Topical liposomal gel of idoxuridine for the treatment of herpes simplex: pharmaceutical and clinical implications. | 2004 Aug |
|
Synchrotron radiation-based experimental determination of the optimal energy for cell radiotoxicity enhancement following photoelectric effect on stable iodinated compounds. | 2004 Aug 2 |
|
Effects of single-pulse (< or = 1 ps) X-rays from laser-produced plasmas on mammalian cells. | 2004 Dec |
|
Positive interactive radiosensitisation in vitro with the combination of two nucleoside analogues, (E)-2'-deoxy-2'-(fluoromethylene) cytidine and iododeoxyuridine. | 2004 Jul |
|
Feasibility of sodium/iodide symporter gene as a new imaging reporter gene: comparison with HSV1-tk. | 2004 Mar |
|
[The latest in herpes simplex keratitis therapy]. | 2004 May |
|
Polyphosphoinositides-dependent regulation of the osteoclast actin cytoskeleton and bone resorption. | 2004 May 13 |
|
Highly efficient DNA incorporation of intratumourally injected [125I]iododeoxyuridine under thymidine synthesis blocking in human glioblastoma xenografts. | 2004 May 20 |
|
[Therapeutic effect of 125IUdR on the glioma cell line C6 in vitro and in vivo]. | 2004 Sep |
|
Overexpression of p27 Kip 1, probability of cell cycle exit, and laminar destination of neocortical neurons. | 2005 Sep |
Sample Use Guides
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/15828168
Antiviral susceptibility of herpes simplex viruses by idoxuridine was studied in human culture cell line WI-38. Eight concentrations were tested, beginning with 1000 ug/ml and subsequent serial one-fourth dilutions. Mean MIC was 0.5 mg/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:40:09 UTC 2023
by
admin
on
Wed Jul 05 22:40:09 UTC 2023
|
Record UNII |
LGP81V5245
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1557
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
||
|
WHO-VATC |
QJ05AB02
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
||
|
NDF-RT |
N0000175459
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
||
|
NDF-RT |
N0000175459
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
||
|
WHO-ATC |
S01AD01
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
||
|
WHO-ATC |
J05AB02
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
||
|
NDF-RT |
N0000175466
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
||
|
WHO-ATC |
D06BB01
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
||
|
NCI_THESAURUS |
C281
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
||
|
NDF-RT |
N0000175459
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
||
|
FDA ORPHAN DRUG |
95696
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
||
|
WHO-VATC |
QS01AD01
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
||
|
WHO-VATC |
QD06BB01
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
39661
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
100000083677
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
1486
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
IDOXURIDINE
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | Description: A white or almost white, crystalline powder. Solubility: Slightly soluble in water, ethanol (~750 g/l) TS and hydrochloric acid (~70 g/l) TS; freely soluble in sodium hydroxide(~80 g/l) TS. Category: Anti-infective agent. Storage: Idoxuridine should be kept in a well-closed container, protected from light. Labeling: The designation Idoxuridine for sterile non-injectable use indicates that the substance complies with the additional requirement and may be used for sterile applications. Expiry date.Additional information: Melting temperature, about 180?C, with decomposition. Requirement: Idoxuridine contains not less than 98.0% and not more than 101.0% of C9H11IN2O5, calculated with reference to the dried substance. | ||
|
LGP81V5245
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
DTXSID2045238
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
LGP81V5245
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
DB00249
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
7479
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
5905
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
D007065
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
1417
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
M6201
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | Merck Index | ||
|
200-207-8
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
SUB08117MIG
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
1336001
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
147675
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
5653
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | RxNorm | ||
|
54-42-2
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
C563
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
CHEMBL788
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY | |||
|
IDOXURIDINE
Created by
admin on Wed Jul 05 22:40:09 UTC 2023 , Edited by admin on Wed Jul 05 22:40:09 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
|
||
|
LABELED -> NON-LABELED |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
LABELED -> NON-LABELED |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|